#USA #Fremont #Alamar Biosciences #NULISAqpcr #Alzheimer's Research

Alamar Biosciences Introduces NULISAqpcr™ AD 5-Plex Assay

Alamar Biosciences, Inc., a leader in precision proteomics, has recently announced a significant advancement in the fight against Alzheimer’s disease with the launch of its NULISAqpcr™ AD 5-plex assay. This innovative research-use-only (RUO) tool is designed to enhance early disease detection through the simultaneous quantitative measurement of five critical blood biomarkers.

What is the NULISAqpcr AD 5-Plex Assay?

The NULISAqpcr AD 5-plex assay aims to consolidate crucial Alzheimer’s biomarkers into a single multiplex format. This assay measures five vital biomarkers:

• - BD-pTau217 (phosphorylated tau derived from the brain)
• - NfL (neurofilament light chain)
• - Aβ42 (beta-amyloid 42)
• - GFAP (glial fibrillary acidic protein)
• - APOE4 (carrier status)

This assay provides researchers with a powerful tool to monitor amyloid pathology, tau neurodegeneration, and inflammation in a cost-effective and efficient manner.

Significance of the Assay’s Features

The NULISAqpcr AD 5-plex is noteworthy not only for its multiplexing capability but also for its unparalleled sensitivity and specificity. Each biomarker it evaluates contributes unique insights related to Alzheimer’s disease pathology. By allowing simultaneous testing of these indicators, researchers can gather a comprehensive view of a patient’s cognitive health from just a single blood or plasma sample.

Dr. Yuling Luo, founder and CEO of Alamar, stated, “The release of this assay marks a pivotal point in our mission to provide precision proteomic solutions for neurodegenerative diseases. By merging vital protein targets into a single assay optimized for streamlined workflows, we empower the neuroscience community to advance the screening, early detection, and precise diagnosis of Alzheimer’s disease.”

In addition to its relevance in Alzheimer’s research, the assay has implications for several other neurodegenerative and cognitive disorders, broadening its potential impact within the scientific community.

Expertise Behind NULISAqpcr Assay

The scientific community at Alamar emphasizes the importance of these blood-based biomarkers in the Alzheimer's research landscape. Dr. Steven Williams, Chief Scientific Officer at Alamar, commented, “Blood biomarkers are transforming the landscape of Alzheimer’s research, providing a precise, affordable, and accessible method for early diagnosis and therapeutic eligibility determination.”

Traditional assays often relied on single-plex methodologies, requiring multiple tests to obtain a complete picture of the disease's progression. With the NULISA™ platform, researchers can analyze multiple Alzheimer-related proteins in blood, transforming how clinicians approach patient diagnosis and management.

Collaborating for Better Outcomes

Alamar Biosciences is dedicated to working in tandem with researchers, healthcare professionals, and industry partners to advance precision proteomics for Alzheimer’s disease and other neurodegenerative conditions. The NULISAqpcr AD 5-plex assay is now available through their Technology Access Program, enabling researchers to incorporate this powerful tool into their studies.

For those interested in comprehensive details about the NULISAqpcr AD 5-plex assay and Alamar's complete range of precision proteomic solutions, visiting www.alamarbio.com is encouraged.

About Alamar Biosciences, Inc.

Alamar Biosciences is a pioneering life sciences company focused on advancing precision proteomics for early disease detection. Utilizing patented NULISA™ technology and the ARGO™ HT system, Alamar’s platform offers ultra-high sensitivity capabilities, addressing key limitations associated with current technologies in precision proteomics. For more information on Alamar’s offerings, please visit www.alamarbio.com.